Amylyx Pharma (AMLX) Announces Interim Data From Ongoing Phase 2 HELIOS Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
- Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose.
Clinical proof-of-concept achieved based on positive data from the first two patients dosed at half the target dose of cells in Part A of Phase 1/2 study - - First patient achieved insulin independence